Benjamin Chong, MD
Dermatology · Dallas, TXNPI 1679782163
Payments from drug & device makers
Across 47 payments — averaging $2626.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$41K
- Astrazeneca UK Limited$24K
- Biogen$23K
- Pfizer$21K
- Amgen$13K
- EMD Serono, Inc.$700
- plus $200 from 2 others
Across 2 payments — averaging $1425.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$2K
- Principia Biopharma Inc.$1K
What the payments were for
- Consulting fees$65,82887%
- Speaking & faculty fees$8,25711%
- Travel & lodging$9711%
- Food & beverage$7401%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 8 | $41,433 |
| Astrazeneca UK Limited | 10 | $23,725 |
| Biogen | 14 | $22,560 |
| Pfizer | 5 | $21,407 |
| Amgen(2 entities) | 3 | $13,398 |
| EMD Serono, Inc. | 2 | $700 |
| AbbVie | 4 | $108 |
| GSK | 1 | $92 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$123,422 in reported general payments places this provider in the 90th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 11 | $74,163 |
| Clobetasol Propionate | 58 | $3,414 |
| Tacrolimus | 25 | $2,353 |
| Acitretin | 11 | $1,818 |
| Ketoconazole | 119 | $1,617 |
| Mycophenolate Mofetil | 12 | $1,044 |
| Hydroxychloroquine Sulfate | 24 | $951 |
| Triamcinolone Acetonide | 98 | $680 |
| Clindamycin Phosphate | 20 | $637 |
| Hydroxyzine Hcl | 11 | $477 |
| Gabapentin | 16 | $260 |
| Mupirocin | 26 | $222 |
| Ammonium Lactate | 16 | $196 |
| Prednisone | 24 | $188 |
| Terbinafine Hcl | 11 | $176 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Dallas
- Jennifer CatherDallas$4.9M
- Martin MenterDallas$3.7M
- So Yeon PaekDallas$3.5M
- Ross RaduskyDallas$3.3M
- Joseph MerolaDallas$2.1M
- William AbramovitsDallas$1.8M
- Donald GlassDallas$847K
- Kristel PolderDallas$761K
- Mary HornerDallas$457K
- Gregory PetersonDallas$412K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.